Evidence map›Paper›PMID 39473102›Full record

ArticleAnti-cancer agents in medicinal chemistry2025

PEGylated Titanium Dioxide Nanoparticle-bound Doxorubicin and Paclitaxel Drugs Affect Prostate Cancer Cells and Alter the Expression of DUSP Family Genes.

Zuhal Tuncbilek, Nese Keklikcioglu Cakmak, Ayca Tas, Durmus Ayan, Yavuz Silig

Abstract read
PubMed Publisher
In one paragraph

Article in Anti-cancer agents in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zuhal TuncbilekDepartment of Chemistry and Chemical Technologies, Yildizeli Vocational School, Sivas Cumhuriyet University, Sivas, 58500, Türkiye.ORCID 0000-0002-6510-0884
Nese Keklikcioglu CakmakDepartment of Chemical Engineering, Faculty of Engineering, Sivas Cumhuriyet University, Sivas, 58140, Türkiye.ORCID 0000-0002-8634-9232
Ayca TasDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Sivas Cumhuriyet University, Sivas, 58140, Türkiye.ORCID 0000-0002-7132-1325
Durmus AyanDepartment of Medical Biochemistry, Faculty of Medicine, Nigde Omer Halisdemir University, Niğde, 51240, Türkiye.ORCID 0000-0003-2615-8474
Yavuz SiligDepartment of Medical Biochemistry, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, 58140, Türkiye.ORCID 0000-0002-0562-7457

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PC) is among the cancer types with high incidence and mortality. New and effective strategies are being sought for the treatment of deadly cancers, such as PC. In this context, the use of nanocarrier systems containing titanium dioxide (TiO

objectiveThis study aimed to evaluate the cytotoxic activity of doxorubicin (DOX) and paclitaxel (PTX) drugs on the PC cell line by attaching them to PEGylated TiO

methodsFree DOX and PTX drugs, DOX and PTX compounds bound to the pegylated TiO

resultsThe cytotoxic activity of PTX compound bound to PEGylated TiO

conclusionAccordingly, it was predicted that the PEGylated TiO

Indexed as

Antineoplastic AgentsDoxorubicinDual-Specificity PhosphatasesNanoparticlesPaclitaxelPolyethylene GlycolsProstatic NeoplasmsTitaniumCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMaleMolecular Docking SimulationAntineoplastic AgentsDoxorubicinDual-Specificity PhosphatasesPaclitaxelPolyethylene GlycolsTitaniumtitanium dioxideanticancer activity.DUSPsgene expressionmolecular dockingnano-based drug carrierProstate cancer

Identifiers

PMID39473102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.